Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma

Documenti analoghi

• Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
  di: Ola Landgren, et al.
  Pubblicazione: (2025)
• Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
  di: Elias K. Mai, et al.
  Pubblicazione: (2024)
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
  di: Niels W. C. J. van de Donk, et al.
  Pubblicazione: (2025)
• European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
  di: Niccolò Bolli, et al.
  Pubblicazione: (2025)
• Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
  di: Meral Beksac, et al.
  Pubblicazione: (2026)